Jaguar Health's Napo Pharmaceuticals to Exhibit at ONS Congress for Cancer Supportive Care

Jaguar Health, Inc. announced that its family company Napo Pharmaceuticals will exhibit at the upcoming Oncology Nursing Society (ONS) Congress in Washington, DC from April 24-28, 2024. This participation underscores Jaguar’s broadened focus from HIV to also include cancer supportive care.

The company plans to begin selling the FDA-approved Gelclair® gel for oral mucositis, commonly called "chemo mouth", starting Q3 2024. Gelclair® is designed to manage pain associated with oral lesions by coating the mouth’s mucosal surface, offering relief without numbing or stinging.

Additionally, the company's novel "Make Cancer Less Shitty" program, initiated in December 2023, aims to highlight gaps in cancer care. According to Jaguar's president and CEO, Lisa Conte, the program embodies a commitment to enhance the quality of life for cancer patients by addressing the side effects of targeted therapies which, despite improving survival rates, often intensify treatment side effects.

The ONS Congress provides a significant platform for professionals striving for excellence in oncology nursing and transformative cancer care, reflecting the event's alignment with Jaguar’s expanding initiatives in supportive care treatments.